Description

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a recombinant peptide analog of human IGF-1, engineered with a substitution of arginine at position 3 and a 13-amino-acid N-terminal extension. These modifications significantly increase its biological half-life (up to ~20–30 hours) and reduce its binding to insulin-like growth factor-binding proteins (IGFBPs), resulting in enhanced bioavailability and potency.

IGF-1 LR3 is involved in mediating many of the anabolic effects of growth hormone, including cellular growth, muscle hypertrophy, protein synthesis, and glucose regulation. It promotes the proliferation and differentiation of satellite cells in muscle tissue, making it relevant in research on muscle repair, tissue regeneration, and anti-catabolic interventions.

Additionally, IGF-1 LR3 has been explored in metabolic and aging studies for its potential to support neuroprotection, bone density, and insulin sensitivity. Due to its powerful growth-promoting properties, it remains a key molecule in experimental endocrinology and regenerative biology.